Objective: To evaluate the efficacy and side effects of artemether combined with primaquine in the treatment of falciparum malaria.
Methods: Randomization and comparison methods were used in 121 falciparum malaria cases in the Republic of Central Africa. Sixty-one cases were treated with artemether combined with primaquine (Group A used artemether orally, Group B used artemether intramuscularly). And 60 cases received single artemether (Group C used artemether orally, Group D used artemether intramuscularly) were taken as control.
Results: In Group A and B the mean fever clearance time were 47.6 +/- 15.7 and 36.9 +/- 10.7 hours, clinical cure rates 84.4% and 100%, relapse rates 6.3% and 3.4%, respectively. In Group C and D the mean fever clearance time were 48.2 +/- 18.4 and 42.2 +/- 9.5 hours, clinical cure rates 90.1% and 96.3%, relapse rates 21.2% and 18.5%, respectively. Side effects in cases of all groups were mild.
Conclusion: Artemether combined with primaquine and single artemether(via both routes) showed good therapeutic effects in falciparum malaria cases, while artemether combined with primaquine was more effective than single artemether in reducing relapes rate of malaria.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unlocking the Therapeutic Benefits of Artemisia Annua: A Comprehensive Overview of its Medicinal Properties.
J Pharm Bioallied Sci
December 2024
Department of Paediatrics, Faculty of Medicine, Sri Lalithambigai Medical College and Hospital, Dr. M.G.R. Educational and Research Institute, Chennai, Tamil Nadu, India.
Artemisia annua L., also referred to as sweet wormwood, sweet annie, sweet sagewort, and annual wormwood (Chinese: qngho), is a species of wormwood native to temperate Asia but naturalised worldwide. It is a member of the Asteraceae family.
View Article and Find Full Text PDFTargeting malaria in high-risk populations in low endemic regions in northern Namibia: a quasi-experimental controlled trial to reduce malaria in seasonal agricultural workers and cattle herders.
BMJ Glob Health
February 2025
Malaria Operational Research Program, Multidisciplinary Research Services, University of Namibia, Windhoek, Khomas, Namibia.
Background: Agricultural worksites are rarely targeted by malaria control programmes, yet may play a role in maintaining local transmission due to workers' high mobility, low intervention coverage and occupational exposures.
Methods: A quasi-experimental controlled intervention study was carried out in farming and cattle herding populations in northern Namibia to evaluate the impact of a targeted malaria intervention package. Eight health facility catchment areas in Zambezi and Ohangwena Regions were randomised to an intervention arm and eligible individuals within worksites in intervention areas received targeted drug administration with artemether-lumefantrine, mop-up indoor residual spraying and long-lasting insecticidal nets, combined with distribution of topical repellent in Zambezi Region.
Dose-Optimization of a Novel Co-Formulated Triple Combination Antimalarial Therapy: Artemether-Lumefantrine-Amodiaquine.
Clin Pharmacol Ther
February 2025
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Artemisinin-based combination therapy (ACT) is the first-line therapy for uncomplicated falciparum malaria, but artemisinin resistance in Asia and now sub-Saharan Africa is threatening our ability to control and eliminate malaria. Triple-ACTs have emerged as a viable alternative treatment to combat declining ACT efficacy due to drug-resistant malaria. In this study, we developed and evaluated an optimal fixed-dose regimen of artemether-lumefantrine-amodiaquine through population pharmacokinetic modeling and simulation.
View Article and Find Full Text PDFPrevalence of Plasmodium falciparum drug resistance markers pfcrt K76T and pfaat1 S258L in southern Rwanda, 2010 to 2023.
J Infect Dis
February 2025
Charité - Universitaetsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Background: In many countries in Sub-Saharan Africa, the Plasmodium falciparum chloroquine resistance marker pfcrt K76T disappeared within a decade of ceased chloroquine use. Pfaat1 S258L has recently been implicated as another chloroquine resistance marker. Both genes may affect parasite susceptibility to partner drugs in artemisinin-based combination therapy.
View Article and Find Full Text PDFAntimalarial therapeutic efficacy studies are vital for monitoring drug efficacy in malaria-endemic regions. The WHO recommends genotyping polymorphic markers including msp-1, msp-2, and glurp for distinguishing recrudescences from reinfections. Recently, WHO proposed replacing glurp with microsatellites (Poly-α, PfPK2, TA1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!